CKD代谢性酸中毒治疗的系统评价与Meta分析
该系统评价与Meta分析纳入14项临床试验(n=1394),评估口服碱剂补充或减少膳食酸摄入对3-5期CKD伴代谢性酸中毒患者的益处与风险。结果显示治疗可提高血清碳酸氢盐、减缓eGFR下降、降低尿白蛋白排泄及ESKD进展风险,但口服碱剂可能加重高血压。
要点
- 口服碱剂或减少膳食酸摄入可提高血清碳酸氢盐水平。
- 治疗可减缓eGFR下降并降低ESKD进展风险(低确定性)。
- 口服碱剂可能与高血压恶化或需增加降压治疗相关(极低确定性)。
核心结论
- 低至中等确定性证据表明,口服碱剂补充或减少膳食酸摄入可能减缓CKD伴代谢性酸中毒患者的肾功能下降速度,并可能降低ESKD风险。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、Embase和Cochrane CENTRAL,纳入14项临床试验(n=1394),对象为3-5期CKD伴代谢性酸中毒(<22 mEq/L)或低正常血清碳酸氢盐(22-24 mEq/L)患者。
- 采用随机效应模型合并数据,连续结局用加权均数差、分类结局用相对危险度及95%CI表示,并用Cochrane偏倚风险和GRADE评估证据质量。
主要发现
- 治疗提高血清碳酸氢盐水平(14项研究,1378例,均数差3.33 mEq/L,95%CI 2.37至4.29)。
- 治疗减缓eGFR下降(13项研究,1329例,均数差-3.28 ml/min per 1.73 m2,95%CI -4.42至-2.14;中等确定性)。
- 治疗降低尿白蛋白排泄(极低确定性)。
- 治疗降低进展至ESKD的风险(相对危险度0.32,95%CI 0.18至0.56;低确定性)。
- 口服碱剂补充与高血压恶化或需增加降压治疗相关(极低确定性)。
临床怎么用
- 对于3-5期CKD伴代谢性酸中毒或低正常血清碳酸氢盐的患者,可考虑口服碱剂补充或减少膳食酸摄入以延缓肾功能下降。
- 使用口服碱剂时需监测血压及降压治疗需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Metabolic acidosis is associated with progression of CKD and has significant adverse effects on muscle and bone. A systematic review and meta-analysis was conducted to evaluate the benefits and risks of metabolic acidosis treatment with oral alkali supplementation or a reduction of dietary acid intake in those with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: MEDLINE, Embase, and Cochrane CENTRAL were searched for relevant trials in patients with stage 3-5 CKD and metabolic acidosis (<22 mEq/L) or low-normal serum bicarbonate (22-24 mEq/L). Data were pooled in a meta-analysis with results expressed as weighted mean difference for continuous outcomes and relative risk for categorical outcomes with 95% confidence intervals (95% CIs), using a random effects model. Study quality and strength of evidence were assessed using Cochrane risk of bias and the Grading of Recommendations Assessment, Development and Evaluation criteria. RESULTS: Fourteen clinical trials were included (n=1394 participants). Treatment of metabolic acidosis with oral alkali supplementation or a reduction of dietary acid intake increased serum bicarbonate levels (14 studies, 1378 patients, mean difference 3.33 mEq/L, 95% CI, 2.37 to 4.29) and resulted in a slower decline in eGFR (13 studies, 1329 patients, mean difference -3.28 ml/min per 1.73 m2, 95% CI, -4.42 to -2.14; moderate certainty) and a reduction in urinary albumin excretion (very-low certainty), along with a reduction in the risk of progression to ESKD (relative risk, 0.32; 95% CI, 0.18 to 0.56; low certainty). Oral alkali supplementation was associated with worsening hypertension or the requirement for increased antihypertensive therapy (very-low certainty). CONCLUSIONS: Low-to-moderate certainty evidence suggest that oral alkali supplementation or a reduction in dietary acid intake may slow the rate of kidney function decline and potentially reduce the risk of ESKD in patients with CKD and metabolic acidosis.
引用
- Navaneethan SD, Shao J, Buysse J, et al. Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2019. PMID: 31196951. doi:10.2215/CJN.13091118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。